SRPT sarepta.com: Business Value to Revenue

Public company logo of Sarepta Therapeutics (SRPT)

The integration of AI into DNA modeling is accelerating drug development, as evidenced by the shift in EV/Sales for Sarepta Therapeutics, Inc. (SRPT). The value of 819.75 reflects the current magnitude of this trend. A monopoly in Duchenne therapy via Elevidys guarantees leadership. High product pricing creates operational leverage, enabling the company to rapidly scale profits and recoup previous R&D expenditures.

SRPT Sarepta Therapeutics Enterprise Value-to-Revenue Ratio (11/23/2025 - 11/21/2026)

Financial and market metric breakdowns for Sarepta Therapeutics (SRPT)

- price and consensus price forecast:
Fundamental valuation:Sarepta Therapeutics, Inc. (SRPT)
Core merchandise of Sarepta

Sarepta Therapeutics, Inc. (SRPT) maintains dominance in the gene therapy segment, enabling the company to command premium pricing for its unique drugs. The EV/Sales metric combines market capitalization and net debt, comparing the total enterprise value to the volume of generated revenue. This indicator determines the price of every dollar of revenue, eliminating the impact of debt load on the valuation. An increase in this ratio reflects market optimism regarding future sales. Analyzing the EV/Sales chart helps identify asset overvaluation or undervaluation in a timely manner.

Competitor analysis for Sarepta Therapeutics, Inc.

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple CRSP|Total Company Value-to-Revenue Ratio GeneDx|Enterprise Value-to-Revenue Ratio Ultragenyx RARE|Total Company Value-to-Revenue Ratio Beam Therapeutics (BEAM)|twistbioscience.com - EV/Sales Multiple|10x Genomics, Inc. - Enterprise Value-to-Revenue Coefficient|NTLA (Intellia Corp) - Company Value to Revenue|Company Value to Revenue stoketherapeutics.com|Company Value to Revenue BLFS|Company Value to Revenue Wave Life Sciences Corp (WVE)|EV/Sales Multiple MAZE|Total Company Value-to-Revenue Ratio Sionna Therapeutics Inc|Enterprise Value-to-Revenue Ratio Prime Medicine Corp PRME|tayshagtx.com (TSHA) - Enterprise Value-to-Revenue Multiple|QURE - Enterprise Value-to-Revenue Ratio|MeiraGTx Holdings (MGTX) - Company Value to Revenue|Regenxbio (RGNX) - Enterprise Value-to-Revenue Ratio|SLDB - Total Company Value-to-Revenue Ratio|OCGN (Ocugen Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio PACB|Enterprise Value-to-Revenue Ratio Benitec (BNTC)|Design Therapeutics Inc - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Rocket Pharma RCKT|EV/Sales Multiple 4DMT FDMT|LXEO - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Korro Bio Inc.|EDIT: EV/Sales Multiple|SLN - Total Company Value-to-Revenue Ratio|PRQR (ProQR Therapeutics) - EV/Sales Multiple|codexis.com (CDXS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple SGMO|EV/Sales Multiple Nautilus Biotechnology, Inc. (NAUT)|EV/Sales Multiple MGX (Metagenomi Inc.)|Business Value to Revenue DTIL|Generation Bio Co. - EV/Sales Multiple|BOLD: Enterprise Value-to-Revenue Ratio|XCUR (Exicure, Inc.) - Company Value to Revenue|Company Value to Revenue Ratio IMNN|Enterprise Value-to-Revenue Ratio RXi Pharmaceuticals|mustangbio.com (MBIO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio TransCode (RNAZ)|Bionano Genomics Inc. - Company Value to Revenue Ratio|Applied DNA Sciences - Company Value to Revenue|Total Company Value-to-Revenue Ratio bluebirdbio.com (BLUE)|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple